Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma

Abstract

To understand the molecular pathways involved in the pathogenesis of squamous cell lung carcinoma, we obtained DNA from 94 microdissected foci from 12 archival surgically resected tumors including histologically normal epithelium (n=13), preneoplastic lesions (n=54), carcinoma is situ (CIS) (n=15) and invasive tumors (n=12). We determined loss of heterozygosity (LOH) at 10 chromosomal regions (3p12, 3p14.2, 3p14.1-21.3, 3p21, 3p22-24, 3p25, 5q22, 9p21, 13q14 RB, and 17p13 TP53) frequently deleted in lung cancer, using 31 polymorphic microsatellite markers, including 24 that spanned the entire 3p arm. Our major findings are as follows: (1) Thirty one percent of histologically normal epithelium and 42% of mildly abnormal (hyperplasia/metaplasia) specimens had clones of cells with allelic loss at one or more regions; (2) There was a progressive increase of the overall LOH frequency within clones with increasing severity of histopathological changes; (3) The earliest and most frequent regions of allelic loss occurred at 3p21, 3p22-24, 3p25 and 9p21; (4) The size of the 3p deletions increased with progressive histologic changes; (5) TP53 allelic loss was present in many histologically advanced lesions (dysplasia and CIS); (6) Analyses of 58 normal and non-invasive foci having any molecular abnormality, indicated that 30 probably arose as independent clonal events, while 28 were potentially of the same clonal origin as the corresponding tumor; (7) Nevertheless, when the allelic losses in the 30 clonally independent lesions and their clonally unrelated tumors were compared the same parental allele was lost in 113 of 125 (90%) of comparisons. The mechanism by which this phenomenon (known as allele specific mutations) occurs is unknown; (8) Four patterns of allelic loss in clones were found. Histologically normal or mildly abnormal foci had a negative pattern (no allelic loss) or early pattern of loss while all foci of CIS and invasive tumor had an advanced pattern. However dysplasias demonstrated the entire spectrum of allelic loss patterns, and were the only histologic category having the intermediate pattern. Our findings indicate that multiple, sequentially occurring allele specific molecular changes commence in widely dispersed, apparently clonally independent foci, early in the multistage pathogenesis of squamous cell carcinomas of the lung.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 5
Figure 4
Figure 6

Similar content being viewed by others

References

  • Adachi JI, Shiseki M, Okazaki T, Ishimuru G, Noguchi M, Hirohashi S and Yokota Y. . 1995 Genes Chromosomes Cancer 14: 301–306.

  • Band PR, Feldstein M and Saccomanno G. . 1986 Cancer Detect. Prevent. 9: 157–160.

  • Birch DE. . 1996 Nature 381: 445–446.

  • Cawkwell L, Lewis FA and Quirke P. . 1994 Br. J. Cancer 70: 813–818.

  • Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R and Rabbitts PH. . 1995 Oncogene 11: 2591–2598.

  • Chung GTY, Sundaresan V, Hasleton P, Rudd R, Taylor R and Rabbitts PH. . 1996 Cancer Res. 56: 1609–1614.

  • Colby TV, Koss MN and Travis WD. . 1995 Tumors of the lower respiratory tract, 3rd series, Fascicle 13. Armed Forces Institute of Pathology, Washington, D.C.

  • Deng G, Lu Y, Zlotnikov G, Thor AD and Smith HS. . 1996 Science 274: 2057–2059.

  • Don RH, Cox PT, Wainwright BJ, Baker K and Mattick JS. . 1991 Nucleic Acids Res. 19: 4008.

  • Fishel R. . 1996 J. Natl. Cancer Inst. 88: 1608–1609.

  • Fisher JC. . 1958 Nature 181: 651–652.

  • Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Tiong Ong S, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF and Minna JD. . 1997 Cancer Res. 57: 2256–2267.

  • Fong KM, Zimmerman PV and Smith PJ. . 1995 Cancer Res. 55: 28–30.

  • Franklin WA, Gasdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM and Miller YE. . 1997 J. Clin. Invest. 100: 2133–2137.

  • Frost JK, Ball WJ, Levin ML, Tockman MS, Erozan YS, Gupta PK, Eggleston JC, Pressman NJ, Donithan MP and Kimball AJ. . 1986 J. Occupat. Med. 28: 692–703.

  • Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD and Gazdar AF. . 1995 JAMA 273: 558–563.

  • Jones MH and Nakamura Y. . 1992 Genes Chromosomes Cancer 5: 89–90.

  • Kishimoto Y, Sugio K, Mitsudomi T, Oyama T, Virmani A, McIntire DD and Gazdar AF. . 1995 J. Natl. Cancer Inst. 87: 1224–1229.

  • Loeb LA. . 1991 Cancer Res. 51: 3075–3079.

  • Loeb LA. . 1994 Cancer Res. 54: 5059–5063.

  • Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F and Sidransky D. . 1994 Proc. Natl. Acad. Sci. USA 91: 9871–9875.

  • Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittleman WN and Hong WK. . 1997 J. Natl. Cancer Inst. 89: 857–862.

  • Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB and Sidransky D. . 1994 Cancer Res. 54: 2098–2101.

  • Minna JD, Sekido Y, Fong K and Gazdar AF. . 1997 Cancer: Principles and Practice of Oncology, 5th edition. DeVita, Jr VT, Hellman S and Rosenberg SA (eds).. Lippincott: Philadelphia pp 849–857.

    Google Scholar 

  • Miozzo M, Sozzi G, Musso K, Pilotti S, Incarbone M, Pastorino U and Pierotti MA. . 1996 Cancer Res. 56: 2285–2288.

  • Nowell PC. . 1976 Science 194: 23–28.

  • Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K. . 1996 Cell 84: 587–597.

  • Parker SL, Tong T, Bolden S and Wingo PA. . 1997 CA Cancer J. Clin. 47: 5–27.

  • Parkin DM, Pisani P, Lopez AD and Masuyer E. . 1994 Int. J. Cancer 5904: 494–504.

  • Risse E, Vooijs G and van't Hof M. . 1988 Acta Cytol. 32: 629–634.

  • Saccomanno G, Archer VE, Auerbach O, Saunders RP and Brennan LM. . 1974 Cancer 33: 256–270.

  • Siegel S . 1956 Nonparametric Statistics for the Behavioural Sciences. McGraw-Hill International Book Co, New York, NY.

    Google Scholar 

  • Sozzi G, Veronese ML, Negrini M, Baffa R, Corticelli MG, Inoue H, Tornielli S, Pilotti S, Ohta M, Huebner K and Croce CM. . 1996 Cell 85: 17–26.

  • Strong MS, Incze J and Vaughan CW. . 1984 J. Otolaryng. 13: 1–6.

  • Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehan NM and Rabbitts P. . 1992 Oncogene 7: 1989–1997.

  • Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B and S, L. . 1995 Cancer Res. 55: 5133–5139.

  • Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW and Dryja TP. . 1993 Genomics 17: 535–543.

  • Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y and White R. . 1989 Science 244: 207–211.

  • Wistuba II, Behrens C, Milchgrub S, Virmani A, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD and Gazdar AF. . 1998 JAMA 279: 1554–1559.

  • Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD and Gazdar AF. . 1997a J. Natl. Cancer Inst. 89: 1366–1373.

  • Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD and Gazdar AF. . 1997b Cancer Res. 57: 3154–3158.

  • Wistuba II, Sugio KH, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J and Gazdar AF. . 1995 Cancer Res. 55: 2511–2515.

Download references

Acknowledgements

Supported by Specialized Program of Research Excellence grant P50-CA70907 and by Public Health Service contract N01CN45580-01 from the National Cancer Institute, National Institutes of Health, Bethesda, MD. We thank the Parkland Hospital Tumor Registry for clinical data collection.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wistuba, I., Behrens, C., Milchgrub, S. et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18, 643–650 (1999). https://doi.org/10.1038/sj.onc.1202349

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202349

Keywords

This article is cited by

Search

Quick links